Envista Holdings Corporation NVST
Composite 59/100; the shares have moved about 36% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 49/100 — a slight mark against it.
Balance-sheet strength ranks 72/100 — a moderate point in its favour. Momentum ranks 67/100 — a moderate point in its favour. Growth ranks 65/100 — a moderate point in its favour.
Quality ranks 49/100 — a slight mark against it.
What the company does Envista Holdings (NVST) designs, makes, and sells dental products across two segments: Specialty Products & Technologies (implants, biomaterials, orthodontics) and Equipment & Consumables (digital imaging, endodontics, consumables). Its brands include Nobel Biocare, Ormco, and Spark.
Key financials NVST posts gross margin 55.3%, operating margin 9.9%, and net margin 2.4%. Revenue grew 14.4% YoY while EPS surged 130.0%. ROE is 2.2%, ROA 3.0%, and ROCE 4.6%, with debt/equity at 0.52 and current ratio 2.44.
Stock health Momentum is positive: +7.26% over 3m, +15.37% over 6m, and +36.85% over 12m, though down 8.68% from the 52-week high. RSI(14) is 61.30. Sideravia scores Quality 42.1 (weak), Growth 67.4, Strength 64.0, Valuation 49.9, Momentum 66.4, and Income 50.0.
Price vs fair value NVST trades at a discount of 10.60% to our fair-value estimate and a discount of 5.93% to the 12-month analyst target. - Fair-value estimate implies 10.60% upside (Sideravia) - 14 analysts set a 12-month target 5.93% above the current price (Sideravia) - Recent Zacks piece highlights a 5.2% single-day gain (Zacks 2026-07-30) - StockStory flags it as a cash-producing stock worth investigating (StockStory 2026-07-31)
Looking forward Forward P/E of 20.33 (vs trailing 64.22) and EV/EBITDA of 12.35 suggest valuation compression as earnings normalize. Growth remains robust, but margins and ROIC metrics lag quality peers, keeping the stock fairly valued despite momentum.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.